Joel Kassimir
Dermatology · New York, NYNPI 1346338480
Payments from drug & device makers
Across 248 payments — averaging $28.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Merz North America, Inc.$644
- Revance Therapeutics, Inc.$542
- Galderma Laboratories, L.p.$327
- Aclaris Therapeutics, Inc.$158
- Pfizer$106
- plus $217 from 9 others
What the payments were for
- Consulting fees$2,82540%
- Travel & lodging$2293%
- Food & beverage$3,96857%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 172 | $5,028 |
| Merz North America, Inc. | 19 | $644 |
| Revance Therapeutics, Inc. | 7 | $542 |
| Galderma Laboratories, L.p. | 15 | $327 |
| Aclaris Therapeutics, Inc. | 17 | $158 |
| Pfizer | 5 | $106 |
| Sun Pharmaceutical Industries Inc. | 3 | $45 |
| Incyte Corporation | 2 | $43 |
| Lilly USA, LLC | 2 | $39 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Encore Dermatology Inc. | 1 | $20 |
| Journey Medical Corporation | 1 | $13 |
| LEO Pharma Inc. | 1 | $13 |
| Mission Pharmacal Company | 1 | $12 |
| VYNE Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$3,179
- DAXXIFY$435
- XEOMIN$252
- BOTOX$150
How this compares
$7,022 in reported general payments places this provider in the 65th percentile of 1,151 dermatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Finasteride | 659 | $9,252 |
| Doxycycline Ir-DrDoxycycline Monohydrate | 13 | $6,786 |
| Spironolactone | 367 | $5,727 |
| Clobetasol Propionate | 78 | $3,993 |
| Dutasteride | 103 | $3,730 |
| Fluorouracil | 61 | $3,728 |
| Minoxidil | 307 | $2,495 |
| ValacyclovirValacyclovir Hcl | 44 | $2,446 |
| Gentamicin Sulfate | 19 | $601 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 20 | $433 |
| Fluocinolone Acetonide | 21 | $432 |
| Doxycycline Hyclate | 30 | $261 |
| Imiquimod | 11 | $211 |
| Mupirocin | 18 | $169 |
| Ketoconazole | 11 | $143 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New York
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- Neil SadickNew York$4.2M
- Orit MarkowitzNew York$3.7M
- Alexandra GolantNew York$3.6M
- George HanNew York$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.